183 related articles for article (PubMed ID: 37729434)
1. TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Wu G; Yoshida N; Liu J; Zhang X; Xiong Y; Heavican-Foral TB; Mandato E; Liu H; Nelson GM; Yang L; Chen R; Donovan KA; Jones MK; Roshal M; Zhang Y; Xu R; Nirmal AJ; Jain S; Leahy C; Jones KL; Stevenson KE; Galasso N; Ganesan N; Chang T; Wu WC; Louissaint A; Debaize L; Yoon H; Dal Cin P; Chan WC; Ho Sui SJ; Ng SY; Feldman AL; Horwitz SM; Adelman K; Fischer ES; Chen CW; Weinstock DM; Brown M
Sci Transl Med; 2023 Sep; 15(714):eadi7244. PubMed ID: 37729434
[TBL] [Abstract][Full Text] [Related]
2. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
[TBL] [Abstract][Full Text] [Related]
3. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
4. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
6. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing.
Peterson JF; Pearce KE; Meyer RG; Greipp PT; Knudson RA; Baughn LB; Ketterling RP; Feldman AL
Histopathology; 2020 Feb; 76(3):481-485. PubMed ID: 31557339
[TBL] [Abstract][Full Text] [Related]
9. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken AP; Pasini D; Capra M; Prosperini E; Colli E; Helin K
EMBO J; 2003 Oct; 22(20):5323-35. PubMed ID: 14532106
[TBL] [Abstract][Full Text] [Related]
10. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
12. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
Caganova M; Carrisi C; Varano G; Mainoldi F; Zanardi F; Germain PL; George L; Alberghini F; Ferrarini L; Talukder AK; Ponzoni M; Testa G; Nojima T; Doglioni C; Kitamura D; Toellner KM; Su IH; Casola S
J Clin Invest; 2013 Dec; 123(12):5009-22. PubMed ID: 24200695
[TBL] [Abstract][Full Text] [Related]
13. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
Nakagawa M; Kitabayashi I
Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
[TBL] [Abstract][Full Text] [Related]
16. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
17. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
20. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]